TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

21 11 2024 14:59:43 提供 Nasdaq GlobeNewswire

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

19 11 2024 15:50:42 提供 Nasdaq GlobeNewswire

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

14 11 2024 16:00:38 提供 Nasdaq GlobeNewswire

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

14 11 2024 14:49:39 提供 Nasdaq GlobeNewswire

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

08 11 2024 14:36:48 提供 Nasdaq GlobeNewswire

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

05 11 2024 15:43:31 提供 Nasdaq GlobeNewswire

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

05 11 2024 08:27:48 提供 Nasdaq GlobeNewswire

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

04 11 2024 13:36:34 提供 Nasdaq GlobeNewswire

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

31 10 2024 09:54:56 提供 Nasdaq GlobeNewswire

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

29 10 2024 14:28:32 提供 Nasdaq GlobeNewswire

Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

29 10 2024 11:43:30 提供 Nasdaq GlobeNewswire

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

25 10 2024 16:34:17 提供 Nasdaq GlobeNewswire

Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

23 10 2024 07:35:00 提供 Nasdaq GlobeNewswire

Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week

22 10 2024 13:30:00 提供 Nasdaq GlobeNewswire

Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

21 10 2024 14:58:22 提供 Nasdaq GlobeNewswire

Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

21 10 2024 12:56:12 提供 Nasdaq GlobeNewswire

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

18 10 2024 21:46:52 提供 Nasdaq GlobeNewswire

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

17 10 2024 08:32:57 提供 Nasdaq GlobeNewswire

Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion

17 10 2024 06:54:51 提供 Nasdaq GlobeNewswire

Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality

16 10 2024 15:30:14 提供 Nasdaq GlobeNewswire